Children's Medical Center Corporation

Dana-Farber-Cancer Institute Inc.

Carla F Kim

Glenn Dranoff

Kwok-kin Wong

Peter Hammerman

Sharon M Louie

David Raiser

Christine M Fillmore

Samuel P Rowbotham

Christine F Brainson

Joo-Hyeon Lee

Chunxiao Xu

Erhan Ararat

Described herein are methods and compositions relating to the provision and/or differentiation of certain fully differentiated lung cell types, including surfactant producing cells (e.g. club secretory cells), mucus producing (Goblet) cells, mucus-producing goblet like cells, and beating ciliated cells. In some embodiments, one or more of the differentiated lung cell types is present in an organoid. Differentiation of these lung cell types can be induced by contacting lung stem and/or progenitor cells with one or more inhibitors of H3K9me1/2 methyltransferase, e.g., an inhibitor of G9a and/or G1p (EMHT2 and/or EHMT1).

Methods and compositions relating to lung cell differentiation

Various aspects described herein provide methods of generating alveolar or alveolar/airway organoids from a population of lung cells to differentiate into alveolar or alveolar/airway organoids. Also provided herein are methods and compositions for treating lung disease comprising transplantation of the alveolar or alveolar/airway organoids, or a cell isolated therefrom to a subject.

Use of alveolar or airway organoids for the treatment of lung diseases and disorders

The present invention is based on the identification of novel biomarkers predictive of responsiveness to anti-immune checkpoint inhibitor therapies.

Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response

The technology described herein is directed to the treatment of cancer, e.g. methods and assays relating to selecting and administering a chemotherapy with or without an EZH2 inhibitor.

Methods and assays for combination treatment of cancer

Growing community of inventors

Boston, MA, United States of America

Carla F Kim